Skip to content

Study · Non-randomized trial · n = 63 · 2008

2 results

Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study.

Garnero P, Bauer DC, Mareau E, Bilezikian JP, Greenspan SL, Rosen C, Black D

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Sept 2008Cited by 23 (Europe PMC)

PMID18442311 (opens in a new tab)PMCIDPMC2683159 (opens in a new tab)DOI10.1359/jbmr.080413 (opens in a new tab)PepBankPUB-18442311
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with osteoporosis, urinary alphaalpha/betabeta CTX ratio did not change significantly during the first year of PTH(1-84).

    In plain wordsIn women with osteoporosis, urinary collagen isomerization ratio did not change significantly during the first year of PTH.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    No significant changeUrinary alphaalpha/betabeta CTX ratio in first year
    Study

    n = 63

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg/d · 1 yearAs given in this study (human).

    Source sentences

    Summary
    During the first year, there was no significant change in alphaalpha/betabeta CTX ratio with PTH or ALN.
    3 context sentences
    Summary · context
    In the first year of the previously published PaTH study, postmenopausal women with osteoporosis were assigned to PTH(1-84) (100 microg/d; n = 119), ALN (10 mg/d; n = 60), or PTH and ALN together (n = 59).
    Summary · context
    We analyzed the effects of PTH(1-84) and ALN on urinary alphaalpha/betabeta CTX ratio, a marker of type I collagen isomerization and maturation in postmenopausal women with osteoporosis.
    Summary · context
    We analyzed patients on ALN alone (n = 60) and a similar number of patients assigned to PTH alone (n = 63).
  2. 02HumanNon-randomized trialEfficacy outcome

    In osteoporotic women receiving PTH(1-84) for one year then placebo, alphaalpha/betabeta CTX ratio increased at 24 mo, with median change +45.5.

    In plain wordsIn women with osteoporosis, collagen isomerization ratio increased after one year of PTH followed by one year of placebo.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseUrinary alphaalpha/betabeta CTX ratio after PTH then placebo
    Study

    n = 31

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg/d · 1 yearAs given in this study (human).

    Measurements

    Median change in alphaalpha/betabeta CTX ratio at 24 mo
    45.5 unit not stated
    PTH(1-84) for first year, then placebo

    Source sentences

    Summary
    At 24 mo, there was a marked increase of the alphaalpha/betabeta CTX ratio in women who had received PTH during the first year, followed by a second year of placebo (median: +45.5, p < 0.001) or ALN (+55.2%, p < 0.001).
    3 context sentences
    Summary · context
    During the second year, women on PTH in the first year were reallocated to placebo (n = 31) or ALN (n = 32) and women with ALN continued on ALN.
    Summary · context
    We analyzed the effects of PTH(1-84) and ALN on urinary alphaalpha/betabeta CTX ratio, a marker of type I collagen isomerization and maturation in postmenopausal women with osteoporosis.
    Summary · context
    We analyzed patients on ALN alone (n = 60) and a similar number of patients assigned to PTH alone (n = 63).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.